



## Press Release

# Cipla appoints Mr. Adil Zainulbhai as an Independent Director on the Board

**India, Mumbai, 25th July, 2014:** Cipla, a global pharmaceutical company is delighted to announce the appointment of Mr. Adil Zainulbhai as an independent director on the Board.

Mr. Adil Zainulbhai retired as Chairman of McKinsey India after a distinguished career consulting Indian corporations and their boards. He spent 24 years in the United States where he led McKinsey's Washington Office and founded the Minneapolis office before returning to India.

Announcing the appointment, **Dr. Y K Hamied, Chairman, Cipla Limited** said: "Adil's 30+ years of experience across various industries in India and globally will add a valuable perspective to our Board of Directors. We warmly welcome him on to the board and look forward to his contribution."

**Mr. Zainulbhai** said "Cipla has had a huge impact in providing affordable pharmaceuticals to the world while building a strong company. I look forward to helping Cipla become even more successful."

Adil counsels the CEOs and promoters of large companies in a range of industries and has helped several such companies become global leaders. He works closely with government leaders to drive growth, raise living standards, strengthen key sectors of the economy and improve healthcare, education, and welfare.

Recently, Adil co-edited the book, 'Reimagining India: Unlocking the potential of Asia's next superpower' a seminal publication of 65 essays from leading thinkers around the world to explore the challenges and opportunities facing the country.

Adil grew up in Bombay and graduated in Mechanical Engineering from the Indian Institute of Technology. He also has an M.B.A. from Harvard Business School.

Adil serves as Independent Director on boards of Reliance Industries, Larsen & Toubro and Network 18 and on boards of numerous non-profit organisations.

## **About Cipla**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in 2013/14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

### **Media Contact:**

Charlotte Chunawala  
Corporate Communications  
Mob: +91 7506257377  
Email: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com)

Jaisingh Balakrishnan  
Corporate Communications  
Mob: +91 9833836185  
Email: [jaisingh.krishnan@cipla.com](mailto:jaisingh.krishnan@cipla.com)